A targeted extracellular vesicles loaded with montelukast in the treatment of demyelinating diseases
Authors:
- 15 January 2022
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 594, 31-37
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learnedFrontiers in Cellular Neuroscience, 2014
- Myelin Recovery in Multiple Sclerosis: The Challenge of RemyelinationBrain Sciences, 2013
- Montelukast for the treatment of asthma in the adult populationExpert Opinion on Pharmacotherapy, 2011
- Delivery of siRNA to the mouse brain by systemic injection of targeted exosomesNature Biotechnology, 2011
- Phenotypic Changes, Signaling Pathway, and Functional Correlates of GPR17-expressing Neural Precursor Cells during Oligodendrocyte DifferentiationJournal of Biological Chemistry, 2011
- A Novel Nanoparticle Drug Delivery System: The Anti-inflammatory Activity of Curcumin Is Enhanced When Encapsulated in ExosomesMolecular Therapy, 2010
- The oligodendrocyte-specific G protein–coupled receptor GPR17 is a cell-intrinsic timer of myelinationNature Neuroscience, 2009
- The P2Y-like receptor GPR17 as a sensor of damage and a new potential target in spinal cord injuryBrain, 2009
- Remyelination capacity of the MS brain decreases with disease chronicityNeurology, 2009
- The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl‐leukotrienes receptorThe EMBO Journal, 2006